Antibiotic development hurt by lack of incentives

The lack of market incentives for new antibiotics is behind the overuse of certain generics, the subsequent drug resistance and weak antibiotic development, writes Trius Therapeutics President and CEO Jeffrey Stein. Health care providers expect antibiotics to be cheap, and that undermines innovation.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief: